RESUMO
Recently, growing interest in polymers (natural and synthetic) as drug carriers in controlled release formulations and drug targeting systems that may improve the efficacy of treatment and reduce the side effects of a drug therapy, has been observed. Special attention has been paid to improving the effectiveness of antibiotics, which constitute a very important, often life-saving group of drugs. In this paper, we review polymers as macromolecular carriers of fluoroquinolones, a group of antibiotics with a broad spectrum of activity. We consider both physical intermixtures and chemical conjugates, although we discuss in greater depth the latter type of coupling, in which covalent bonds between drug molecules and polymers occur.
Assuntos
Antibacterianos/administração & dosagem , Sistemas de Liberação de Medicamentos , Fluoroquinolonas/administração & dosagem , Animais , Humanos , Polímeros/administração & dosagemRESUMO
This work is a continuation of our previous research, concentrating this time on lead structure modification to increase the 5-HT1A receptor affinity and water solubility of designed compounds. Therefore, the compounds synthesised within the present project included structural analogues of 3ß-acylamine derivatives of tropane with the introduction of a methyl substituent in the benzyl ring and a 2-quinoline, 3-quinoline, or 6-quinoline moiety. A series of novel 3ß-aminotropane derivatives was evaluated for their affinity for 5-HT1A, 5-HT2A, and D2 receptors, which allowed for the identification of compounds 12e, 12i, and 19a as ligands with highest affinity for the tested receptors; they were then subjected to further evaluation in preliminary in vivo studies. Selected compounds 12i and 19a displayed antipsychotic properties in the d-amphetamine-induced and MK-801-induced hyperlocomotor activity test in mice. Moreover, compound 19a showed significant antidepressant-like activity in the forced swim test in mice.
RESUMO
This study presents TLC, HPLC-DAD and HPLC-FT-IR analyses concerning the detection, identification and determination of organic impurities of commercial tropicamide ((R,S)-N-ethyl-3-hydroxy-2-phenyl-N-(4-pyridylmethyl)propanamide) as a medical substance designed for the production of eye drops. In the examined samples from several random production batches, only one impurity (defined by Ph. Eur. 6th Ed.) was discovered in the amount sufficient for the quantitative analysis. On the basis of comparison of retention times, UV and IR spectra of the impurity and its synthesized standard, this impurity was identified as apotropicamide (N-ethyl-2-phenyl-N-(4-pyridylmethyl)prop-2-enamide). For the chemical identification of organic compounds occurring in the tropicamide samples, an off-line coupling of HPLC with FT-IR was used. The structure of a standard of apotropicamide was confirmed by (1)H NMR and (13)C NMR analysis. Validation of the HPLC-DAD method of determination both tropicamide and apotropicamide in the tropicamide medical substance was performed. This method is suitable for use in the quality control of tropicamide during its production.